Igor Samatoshenkov | Medicine | Best Researcher Award

Mr. Igor Samatoshenkov | Medicine | Best Researcher Award

Vascular surgeon, Uniclinic Brandenburg, Medical school Brandenburg, Germany

Dr. Samatoshenkov Igor Valeryevich  is an accomplished cardiovascular surgeon, innovator, and medical entrepreneur, currently based in Brandenburg, Germany. With an MD and PhD in medical sciences, he has made significant strides in the fields of vascular surgery, regenerative medicine, and gene therapy. He is the founder and CEO of “Angiolife,” a Skolkovo-based biotech company pioneering gene-drug research. As a dedicated academic and clinical expert, Dr. Samatoshenkov has been actively involved in cutting-edge surgical practice, scientific research, and medical education. 🧬💉

Publication Profile

Scopus

ORCID

🎓 Education Background

Dr. Samatoshenkov earned his PhD in 2021 from Kazan Federal University 🎓. His earlier training includes a medical degree from Kazan State Medical University (2009–2015), where he also specialized as a professional medical translator (2012–2014). He pursued advanced phlebology training in endovenous laser obliteration in 2018 in Moscow. His comprehensive education has built a solid foundation for his clinical and research pursuits. 📚🩺

💼 Professional Experience

Dr. Samatoshenkov has over a decade of experience in cardiovascular surgery and medical education. Since 2017, he has been serving in the Department of Cardiosurgery No. 1 and is a graduate student in the Department of Histology, Cytology, and Embryology. From 2015 to 2017, he was an attending physician in the Department of Heart Surgery at the ICDC. He also contributed to academia as an assistant in the Department of Normal Anatomy (2016–2017) and led several student scientific circles from 2011 to 2014. In 2018, he founded “Angiolife,” advancing gene-based therapeutics. 🏥💡

🏆 Awards and Honors

Dr. Samatoshenkov’s innovations have been widely recognized. He won the 2023 National Competition of Innovative Ideas in Medicine by AMTEC Foundation 🏅 and the “Top 50 Innovative Ideas” contest in Tatarstan 🥇. He was a finalist in the 2022 MEDLEADS competition and ranked 2nd in the 2021 All-Russian Intellectual Property contest “Intellect.” He also received accolades from the Academy of Sciences of Tatarstan (2020) and Innopolis Startup Tour (3rd place). 🌟🔬

🔬 Research Focus

Dr. Samatoshenkov’s research spans cardiovascular regeneration, gene and stem cell therapy, and surgical innovation. His pioneering studies in VEGF, ANG, and GDNF gene delivery have opened promising avenues in post-ischemic tissue recovery. His experimental models and cell-mediated delivery techniques are pushing the boundaries of modern medicine. 🧪🧠

🔚 Conclusion

With an exceptional blend of clinical excellence, scientific ingenuity, and entrepreneurial vision, Dr. Igor Samatoshenkov is a leading figure in cardiovascular innovation and regenerative therapy. His mission continues to bridge advanced research with real-world patient solutions. 🌐

📘 Top Publications

  1. Modeling of acute venous lesion of the lower extremities in experiment (2016) – Clinical and Experimental Surgery
    Authors: I.V. Samatoshenkov, B.M. Mirolyubov
    Cited by: —
    Journal Link: Not publicly available online

  2. Effects of direct and indirect delivery of the VEGF gene by cord blood cells to the area of limb ischemia in rats (2017) – Morphological Statements
    Authors: I.V. Samatoshenkov, S.A. Andreev, N.V. Boychuk
    🔗 https://doi.org/10.20340/mv-mn.2017(25).4.14-17
    Cited by: 5+

  3. Comparison of the effectiveness of stimulating angiogenesis in ischemic limbs… (2019) – Creative Cardiology
    Authors: I.V. Samatoshenkov et al.
    🔗 https://doi.org/10.24022/1997-3187-2019-13-3-250-262
    Cited by: 10+

  4. Stimulation of angiogenesis of rat skeletal muscle… (2020) – Morphology
    🔗 https://doi.org/10.34922/AE.2020.157.1.006
    Cited by: 15+

  5. Adenoviral vector delivery of VEGF, angiogenin, and GDNF genes promotes angiogenesis… (2020) – BioNanoScience
    Authors: I.V. Samatoshenkov et al.
    🔗 https://doi.org/10.1007/s12668-019-00688-y
    Cited by: 25+

  6. New experimental model of hind limb ischemia in pot-bellied pigs (2023) – Microvascular Research
    Authors: Igor Samatoshenkov et al.
    🔗 https://doi.org/10.1016/j.mvr.2022.104425
    Cited by: 8+

  7. Combined delivery of the VEGF, ANG, and GDNF genes stimulates angiogenesis and post-ischemic regeneration (2024) – Current Issues in Molecular Biology
    🔗 https://doi.org/10.3390/cimb46080507
    Cited by: 12+

 

Dr. Lova Kajuluri | Medicine | Best Researcher Award

Dr. Lova Kajuluri | Medicine | Best Researcher Award

Postdoctoral Research Fellow, Mass General Brigham, United States

Lova Prasadareddy Kajuluri is a Postdoctoral Research Fellow at the Cardiovascular Research Center, Massachusetts General Hospital (MGH), Charlestown, USA. He is recognized for his significant contributions to cardiovascular research, particularly in understanding vascular calcification and its potential treatments. With a strong background in biotechnology, Kajuluri has advanced in his research career through various prestigious roles in both India and the United States. He holds a Doctorate in Science from the CSIR-Central Drug Research Institute, Lucknow, India, and has received multiple research grants to further his studies in cardiovascular diseases. 🚀

Publication Profile

Education Background

Kajuluri’s educational journey began with a Bachelor of Science in Biotechnology, Biochemistry, and Chemistry from Andhra University in 2007. He continued to pursue a Master of Science in Biotechnology from Andhra University, followed by a Ph.D. in Science from CSIR-Central Drug Research Institute, India. His academic excellence has paved the way for several postdoctoral positions, starting from his research fellowship at Boston University to his current position at Massachusetts General Hospital, where he continues to explore novel therapies in cardiovascular research. 🎓📚

Professional Experience

Kajuluri’s professional career began as a Research Fellow at CSIR-Central Drug Research Institute in India, focusing on Leishmaniasis and actin-related proteins. He transitioned to postdoctoral research at Boston University, where he led studies on vascular smooth muscle contraction and calponin. His current role as a Postdoctoral Research Fellow at MGH involves leading studies on vascular calcification, gene therapy, and identifying therapeutic targets to treat cardiovascular diseases. His extensive research in these areas contributes significantly to the advancement of vascular health. 🔬🧑‍🔬

Awards and Honors

Kajuluri has received numerous prestigious awards throughout his career. Notably, he was awarded the Research Fellowship from the University Grants Commission, New Delhi, India (2011-2016). He has also been a part of several funded research projects, including those supported by the National Heart, Lung, and Blood Institute, USA. His dedication to advancing cardiovascular and infectious disease research has earned him recognition from the scientific community. 🏆🎖️

Research Focus

Kajuluri’s research is focused on understanding the molecular mechanisms underlying vascular calcification, a condition that contributes to cardiovascular diseases. His current studies explore gene therapies to treat vascular calcification in infants, as well as the role of histone deacetylases in vascular health. Additionally, his earlier work in Leishmaniasis has expanded his expertise to parasitology and cellular biology. His work bridges cardiovascular research and therapeutic innovation, offering potential treatments for critical vascular conditions. ❤️🧬

Conclusion

Lova Prasadareddy Kajuluri’s career is a testament to his commitment to advancing science in cardiovascular health and infectious diseases. Through his research, he continues to provide invaluable insights into vascular calcification and gene therapy, offering hope for future treatments in these fields. 🌟🔬

Publication Top Notes

Epigenetic Regulation of Human Vascular Calcification. Genes, 2025, 16, 506. DOI

Calponin 1 inhibits agonist-induced ERK activation and decreases calcium sensitization in vascular smooth muscle.  Journal of Cellular and Molecular Medicine, January 28, 2024. PubMed

Treatment of calcific arterial disease via enhancement of autophagy using GSK343.  iScience, October 28, 2023. PubMed

Intracellular localization of MyosinXXI discriminates Leishmania spp and Leptomonas seymouri.  Biochemical and Biophysical Research Communications, May 14, 2022. PubMed

Actin-related protein 4: An unconventional negative regulator of mitochondrial calcium in protozoan parasite Leishmania.  Mitochondrion, Jan 2022. PubMed

Vascular aging, the vascular cytoskeleton and aortic stiffness.  Exploration of Medicine, June 2021. PubMed

The uterine myocyte, contractile machinery and proteins of the myometrium and their relationship to the dynamic nature of myometrial function.  Current Opinion in Physiology, February 2020. ScienceDirect

A twinfilin-like protein coordinates karyokinesis by influencing mitotic spindle elongation and DNA replication in Leishmania.  Molecular Microbiology, April 2016. PubMed

Oligomerization of coronin: Implication on actin filament length in Leishmania. Cytoskeleton (Hoboken, N.J.), December 2015. PubMed